Kingworld Medicines Group Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Kingworld Medicines Group.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare	22.3%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Kingworld Medicines Group (HKG:1110) Takes On Some Risk With Its Use Of Debt

Oct 04

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0338

May 31

Even With A 26% Surge, Cautious Investors Are Not Rewarding Kingworld Medicines Group Limited's (HKG:1110) Performance Completely

May 22

Investors Shouldn't Be Too Comfortable With Kingworld Medicines Group's (HKG:1110) Earnings

Apr 29

Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0338

Apr 23

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Mar 22

The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising

Nov 30

Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement

Aug 17

Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247

May 30

The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing

May 11

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247

Apr 03

Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture

Feb 07

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Oct 07

Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business

Jul 05

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024

Apr 27

We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)

Aug 17

Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly

Apr 24

Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)

Mar 29

Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares

Mar 08

Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?

Feb 15

Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)

Jan 25

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Kingworld Medicines Group no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

SEHK:1110 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2024	1,052	31	44	117	N/A
3/31/2024	1,065	35	-10	80	N/A
12/31/2023	1,079	38	-63	42	N/A
9/30/2023	1,085	37	-15	110	N/A
6/30/2023	1,091	36	34	177	N/A
3/31/2023	1,024	29	64	182	N/A
12/31/2022	958	23	93	187	N/A
9/30/2022	905	29	66	159	N/A
6/30/2022	852	35	40	131	N/A
3/31/2022	850	33	31	106	N/A
12/31/2021	847	30	23	81	N/A
9/30/2021	858	26	76	111	N/A
6/30/2021	868	21	129	141	N/A
3/31/2021	807	17	121	132	N/A
12/31/2020	745	12	114	124	N/A
9/30/2020	749	16	90	99	N/A
6/30/2020	752	20	66	74	N/A
3/31/2020	865	32	95	103	N/A
12/31/2019	978	43	124	133	N/A
9/30/2019	1,010	45	79	88	N/A
6/30/2019	1,041	46	34	44	N/A
3/31/2019	1,060	44	42	53	N/A
12/31/2018	1,079	41	51	62	N/A
9/30/2018	1,079	49	60	85	N/A
6/30/2018	1,079	56	70	108	N/A
3/31/2018	1,055	54	N/A	90	N/A
12/31/2017	1,031	51	N/A	72	N/A
9/30/2017	1,088	50	N/A	58	N/A
6/30/2017	1,145	49	N/A	43	N/A
3/31/2017	1,099	48	N/A	20	N/A
12/31/2016	1,054	47	N/A	-4	N/A
9/30/2016	909	41	N/A	20	N/A
6/30/2016	764	35	N/A	44	N/A
3/31/2016	739	34	N/A	74	N/A
12/31/2015	714	32	N/A	103	N/A
9/30/2015	711	34	N/A	56	N/A
6/30/2015	708	36	N/A	10	N/A
3/31/2015	684	37	N/A	2	N/A
12/31/2014	660	38	N/A	-5	N/A
9/30/2014	640	43	N/A	-21	N/A
6/30/2014	619	48	N/A	-38	N/A
3/31/2014	587	48	N/A	-44	N/A
12/31/2013	555	47	N/A	-50	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de 1110 es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de 1110 crezcan más rápidamente que el mercado Hong Kong

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de 1110 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de 1110 crezcan más rápidamente que el mercado de Hong Kong.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de 1110 crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 1110 se prevé que sea elevada dentro de 3 años.

Kingworld Medicines Group Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Kingworld Medicines Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Kingworld Medicines Group Limited Provides Preliminary Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2020

Recent updates

Kingworld Medicines Group (HKG:1110) Takes On Some Risk With Its Use Of Debt

First half 2024 earnings released: EPS: CN¥0.052 (vs CN¥0.064 in 1H 2023)

Kingworld Medicines Group Limited Appoints Chu Xiaoping as Non-Executive Director and Member of the Nomination, Remuneration and Audit Committee, Effective 1 September 2024

Kingworld Medicines Group Limited Appoints Chu Xiaoping as Non-Executive Director and Member of the Nomination, Remuneration and Audit Committee, Effective 1 September 2024

New minor risk - Earnings quality

Kingworld Medicines Group Limited to Report First Half, 2024 Results on Aug 28, 2024

Now 23% undervalued

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0338

Kingworld Medicines Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Now 22% undervalued

Upcoming dividend of HK$0.034 per share

Even With A 26% Surge, Cautious Investors Are Not Rewarding Kingworld Medicines Group Limited's (HKG:1110) Performance Completely

Investors Shouldn't Be Too Comfortable With Kingworld Medicines Group's (HKG:1110) Earnings

Full year 2023 earnings released: EPS: CN¥0.064 (vs CN¥0.037 in FY 2022)

Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0338

Kingworld Medicines Group Limited, Annual General Meeting, May 29, 2024

Full year 2023 earnings released: EPS: CN¥0.064 (vs CN¥0.037 in FY 2022)

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Kingworld Medicines Group Limited to Report Fiscal Year 2023 Final Results on Mar 26, 2024

Now 29% overvalued

The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising

New minor risk - Share price stability

First half 2023 earnings released: EPS: CN¥0.064 (vs CN¥0.04 in 1H 2022)

Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement

Kingworld Medicines Group Limited to Report First Half, 2023 Results on Aug 28, 2023

Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247

Kingworld Medicines Group Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.025 per share at 3.0% yield

The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247

Full year 2022 earnings released: EPS: CN¥0.037 (vs CN¥0.05 in FY 2021)

Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture

Investor sentiment improved over the past week

Insufficient new directors

Now 22% undervalued after recent price drop

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Now 24% undervalued

First half 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.032 in 1H 2021)

Kingworld Medicines Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Co-Founder recently bought HK$297k worth of stock

Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business

Kingworld Medicines Group Limited Announces Final Cash Dividend for the Financial Year Ended 31 December 2021, Payable on 30 June 2022

Upcoming dividend of HK$0.024 per share

Full year 2021 earnings released: EPS: CN¥0.05 (vs CN¥0.019 in FY 2020)

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024

Less than half of directors are independent

Co-Founder recently bought HK$280k worth of stock

Kingworld Medicines Group Limited Announces Final Dividend for the Year Ended 31 December 2021, Payable on 30 June 2022

Full year 2021 earnings released: EPS: CN¥0.05 (vs CN¥0.019 in FY 2020)

Kingworld Medicines Group Limited, Annual General Meeting, May 27, 2022

Kingworld Medicines Group Limited, Annual General Meeting, May 27, 2022

First half 2021 earnings released: EPS CN¥0.032 (vs CN¥0.016 in 1H 2020)

We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)

Kingworld Medicines Group Limited Declares Final Dividend for the Year Ended December 31, 2020

Full year 2020 earnings released: EPS CN¥0.019 (vs CN¥0.07 in FY 2019)

Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly

Full year 2020 earnings released: EPS CN¥0.019 (vs CN¥0.07 in FY 2019)

Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)

Kingworld Medicines Group Limited Provides Preliminary Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2020

Kingworld Medicines Group Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares

Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?

New 90-day low: HK$0.67

Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)

New 90-day low: HK$0.73

Will the Promising Trends At Kingworld Medicines Group (HKG:1110) Continue?

We Think Kingworld Medicines Group (HKG:1110) Can Stay On Top Of Its Debt

What We Learned About Kingworld Medicines Group's (HKG:1110) CEO Compensation

Kingworld Medicines Group Limited Enters Distribution Agreement with Shenzhen Ausa Pharmaceutical Co., Ltd

Executive Director recently sold HK$1.3m worth of stock

New 90-day high: HK$0.80

First half earnings released

New 90-day low - HK$0.71